AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26354756 — intervention group
Group type: EXPERIMENTAL
Intervention: miR-126-3p, miR-145-5p, miR-223-3p, and miR-199a-5p down-regulation in CD4(+) and CD8(+) T cells (>3-fold change, P<0.05)
Number of subjects: 84
Study 26354756 — intervention group
Group type: EXPERIMENTAL
Intervention: Successful immunosuppressive therapy
Number of subjects: 84
Study 26354756 — intervention group
Group type: EXPERIMENTAL
Intervention: miR-126-3p and miR-145-5p knockdown
Number of subjects: 84
Study 26355142 — intervention group
Group type: EXPERIMENTAL
Intervention: ICD-9 code for CKD stage 3 (585.3)
Number of subjects: 325
Study 26355551 — intervention group
Group type: EXPERIMENTAL
Intervention: ERY-ASP (25-150 IU/kg)
Number of subjects: 12
Study 26355708 — intervention group
Group type: EXPERIMENTAL
Intervention: CD34+ peripheral blood cells analyzed for del(12p) using sequential fluorescence in situ hybridization (FISH) analyses
Number of subjects: 367
Study 26355708 — intervention group
Group type: COMPARATOR
Intervention: CBA (chromosome banding analysis)
Number of subjects: 367
Study 26355708 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated analyses over time
Number of subjects: 367
Study 26355708 — intervention group
Group type: EXPERIMENTAL
Intervention: FISH technique with a suitable probe for ETV6/TEL in 12p13
Number of subjects: 367
Study 26356240 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional endoscopic sinus surgery
Number of subjects: 405
Study 26356802 — intervention group
Group type: EXPERIMENTAL
Intervention: EUSFNA needle without side port (A)
Number of subjects: 30
Study 26356802 — intervention group
Group type: COMPARATOR
Intervention: EUSFNA needle with side port (B)
Number of subjects: 30
Study 26356802 — intervention group
Group type: EXPERIMENTAL
Intervention: Both needles (A and B)
Number of subjects: 30
Study 26356811 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial near-infrared radiation (NIR), 700 mW/cm(2) irradiance, 84 J/cm(2) fluence, total NIR energy of 2.40 kJ delivered per session for 6 sessions
Number of subjects: 4
Study 26356834 — intervention group
Group type: COMPARATOR
Intervention: CHART-2 Study
Number of subjects: 4685
Study 26356834 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of β-blockers in CHART-2 Study
Number of subjects: 4685
Study 26356834 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of statins in CHART-2 Study
Number of subjects: 4685
Study 26357963 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe asthma
Number of subjects: 509
Study 26357963 — intervention group
Group type: COMPARATOR
Intervention: Mild/moderate asthma
Number of subjects: 509
Study 26358172 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriparatide (20 mcg for 18-24 months)
Number of subjects: 21
Study 26358358 — intervention group
Group type: COMPARATOR
Intervention: Fructose (in isocaloric exchange for other carbohydrates)
Number of subjects: 1068
Study 26358358 — intervention group
Group type: COMPARATOR
Intervention: Fructose (in hypercaloric trials)
Number of subjects: 1068
Study 26358885 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioural Indicators of Pain Scale (ESCID)
Number of subjects: 300
Study 26358885 — intervention group
Group type: COMPARATOR
Intervention: Behavioural Pain Scale
Number of subjects: 300
Study 26359009 — intervention group
Group type: EXPERIMENTAL
Intervention: Daptomycin treatment
Number of subjects: 203
Study 26359024 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily insulin detemir (IDet)
Number of subjects: 3272
Study 26359538 — intervention group
Group type: EXPERIMENTAL
Intervention: Texture-location differences
Number of subjects: 0
Study 26359538 — intervention group
Group type: EXPERIMENTAL
Intervention: Texture-type differences
Number of subjects: 0
Study 26359538 — intervention group
Group type: EXPERIMENTAL
Intervention: Distracter texture-location differences
Number of subjects: 0
Study 26359538 — intervention group
Group type: EXPERIMENTAL
Intervention: Distracter texture-type differences
Number of subjects: 0
Study 26359538 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole shapes with texture-location differences
Number of subjects: 0
Study 26359538 — intervention group
Group type: EXPERIMENTAL
Intervention: Separated shape parts at distinct spatial locations
Number of subjects: 0
Study 26360334 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambrisentan 10 mg and Tadalafil 40 mg daily for 36 weeks
Number of subjects: 24
Study 26360731 — intervention group
Group type: EXPERIMENTAL
Intervention: Assertive case management
Number of subjects: 914
Study 26360731 — intervention group
Group type: COMPARATOR
Intervention: Enhanced usual care (control)
Number of subjects: 914
Study 26361391 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.8 mm slice reconstruction
Number of subjects: 50
Study 26361391 — intervention group
Group type: COMPARATOR
Intervention: 4.8 mm slice reconstruction
Number of subjects: 50
Study 26361391 — intervention group
Group type: EXPERIMENTAL
Intervention: Thicker slices with AIF and motion correction based on thin slices
Number of subjects: 50
Study 26361391 — intervention group
Group type: EXPERIMENTAL
Intervention: Thin slice reconstruction
Number of subjects: 50
Study 26361391 — intervention group
Group type: COMPARATOR
Intervention: Thick slice reconstruction
Number of subjects: 50
Study 26361759 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrative cuisine workshop program
Number of subjects: 86
Study 26362511 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive steps/day goals
Number of subjects: 0
Study 26362511 — intervention group
Group type: COMPARATOR
Intervention: Static steps/day goals
Number of subjects: 0
Study 26362511 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate reinforcement
Number of subjects: 0
Study 26362511 — intervention group
Group type: COMPARATOR
Intervention: Delayed reinforcement
Number of subjects: 0
Study 26362616 — intervention group
Group type: EXPERIMENTAL
Intervention: One-stop-shop (OSS) concept using real-time in vivo reflectance confocal microscopy (RCM)
Number of subjects: 0
Study 26362616 — intervention group
Group type: COMPARATOR
Intervention: Current standards of care in diagnosing and treating clinically suspected BCC
Number of subjects: 0
Study 26362616 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative patient satisfaction data
Number of subjects: 0
Study 26362881 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-based assessment of carotid artery plaque (CAP)
Number of subjects: 2216
Study 26362881 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid intima-media thickness (CIMT)
Number of subjects: 2216
Study 26362881 — intervention group
Group type: EXPERIMENTAL
Intervention: Ankle-brachial index (ABI)
Number of subjects: 2216
Study 26362881 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of NCA and typical angina
Number of subjects: 2216
Study 26362881 — intervention group
Group type: EXPERIMENTAL
Intervention: Atypical clinical presentation and lack of NCA
Number of subjects: 2216
Study 26362903 — intervention group
Group type: EXPERIMENTAL
Intervention: Fingolimod treatment (1d)
Number of subjects: 27
Study 26362903 — intervention group
Group type: EXPERIMENTAL
Intervention: Fingolimod treatment (3mo)
Number of subjects: 27
Study 26363331 — intervention group
Group type: EXPERIMENTAL
Intervention: EUS-guided ethanol lavage (EEL) with 80% ethanol
Number of subjects: 23
Study 26363334 — intervention group
Group type: EXPERIMENTAL
Intervention: Colon Capsule Endoscopy (CCE)
Number of subjects: 40
Study 26363334 — intervention group
Group type: COMPARATOR
Intervention: Small-Intestine Contrast Ultrasound (SICUS)
Number of subjects: 40
Study 26363334 — intervention group
Group type: COMPARATOR
Intervention: Magnetic Resonance Enterography (MRE)
Number of subjects: 40
Study 26363334 — intervention group
Group type: COMPARATOR
Intervention: Ileocolonoscopy
Number of subjects: 40
Study 26363342 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of autologous, unfractionated bone marrow
Number of subjects: 6
Study 26363547 — intervention group
Group type: EXPERIMENTAL
Intervention: Biotin-labeled autologous neonatal red blood cells (BioRBC)
Number of subjects: 15
Study 26363547 — intervention group
Group type: COMPARATOR
Intervention: Biotin-labeled allogeneic adult red blood cells (BioRBC)
Number of subjects: 15
Study 26363548 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB)
Number of subjects: 22
Study 26363834 — intervention group
Group type: EXPERIMENTAL
Intervention: Upstream-dominant lesions
Number of subjects: 81
Study 26363834 — intervention group
Group type: EXPERIMENTAL
Intervention: Downstream-dominant lesions
Number of subjects: 81
Study 26363834 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall correlation
Number of subjects: 81
Study 26363834 — intervention group
Group type: COMPARATOR
Intervention: Pressure gradient, FFRCT, and wall shear stress
Number of subjects: 81
Study 26363834 — intervention group
Group type: COMPARATOR
Intervention: Distribution of APS
Number of subjects: 81
Study 26363838 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 26363899 — intervention group
Group type: EXPERIMENTAL
Intervention: Inclacumab 0.3 mg/kg
Number of subjects: 62
Study 26363899 — intervention group
Group type: EXPERIMENTAL
Intervention: Inclacumab 3.0 mg/kg
Number of subjects: 62
Study 26363899 — intervention group
Group type: EXPERIMENTAL
Intervention: Inclacumab 20 mg/kg
Number of subjects: 62
Study 26363899 — intervention group
Group type: EXPERIMENTAL
Intervention: Inclacumab (all doses)
Number of subjects: 62
Study 26363929 — intervention group
Group type: EXPERIMENTAL
Intervention: Step-up FMT strategy
Number of subjects: 15
Study 26364279 — intervention group
Group type: EXPERIMENTAL
Intervention: Powered exoskeleton (ReWalk) with Lofstrand crutches
Number of subjects: 12
Study 26364679 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic mucosal resection (EMR)
Number of subjects: 1353
Study 26364679 — intervention group
Group type: COMPARATOR
Intervention: Surgery (control)
Number of subjects: 1353
Study 26364690 — intervention group
Group type: COMPARATOR
Intervention: Mobile group (N=7)
Number of subjects: 32
Study 26364690 — intervention group
Group type: EXPERIMENTAL
Intervention: Training group (N=16)
Number of subjects: 32
Study 26364690 — intervention group
Group type: COMPARATOR
Intervention: Control group (N=9)
Number of subjects: 32
Study 26364966 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic clips used during EMR
Number of subjects: 111
Study 26364966 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic clips used during EMR for prophylaxis of bleeding
Number of subjects: 111
Study 26364966 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of residual clips
Number of subjects: 111
Study 26364966 — intervention group
Group type: EXPERIMENTAL
Intervention: Female sex
Number of subjects: 111
Study 26364966 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater age
Number of subjects: 111
Study 26364984 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Methadone (0.1 mg/kg per dose every 6 hours)
Number of subjects: 0
Study 26364984 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimized dosing strategies based on simulated PK profiles
Number of subjects: 0
Study 26365536 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI)
Number of subjects: 80
Study 26366204 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term HRV test
Number of subjects: 56
Study 26366204 — intervention group
Group type: COMPARATOR
Intervention: Ewing's test
Number of subjects: 56
Study 26366430 — intervention group
Group type: EXPERIMENTAL
Intervention: Maraviroc 600 mg twice daily
Number of subjects: 276
Study 26366430 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 276
Study 26366956 — intervention group
Group type: EXPERIMENTAL
Intervention: Management strategies proposed by authors
Number of subjects: 0
Study 26366956 — intervention group
Group type: COMPARATOR
Intervention: Current guidelines
Number of subjects: 0
Study 26367141 — intervention group
Group type: EXPERIMENTAL
Intervention: ShangRing circumcision
Number of subjects: 194
Study 26367187 — intervention group
Group type: EXPERIMENTAL
Intervention: Voluntary Medical Male Circumcision (VMMC) using the Forceps Guided Method Under Local Anesthesia
Number of subjects: 454
Study 26367187 — intervention group
Group type: EXPERIMENTAL
Intervention: Voluntary Medical Male Circumcision (VMMC)
Number of subjects: 454
Study 26367236 — intervention group
Group type: EXPERIMENTAL
Intervention: Treosulfan, etoposide and cyclophosphamide
Number of subjects: 50
Study 26368663 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil in PD group
Number of subjects: 31
Study 26368663 — intervention group
Group type: COMPARATOR
Intervention: Remifentanil in NPD group
Number of subjects: 31
Study 26369751 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal left ventricular filling pressure (Group A)
Number of subjects: 57
Study 26369751 — intervention group
Group type: COMPARATOR
Intervention: Elevated left ventricular filling pressure (Group B)
Number of subjects: 57
Study 26370823 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.9% saline
Number of subjects: 3116
Study 26370823 — intervention group
Group type: COMPARATOR
Intervention: calcium-free balanced solution
Number of subjects: 3116
Study 26370838 — intervention group
Group type: EXPERIMENTAL
Intervention: Afucosylated anti-BCMA monoclonal antibody conjugated with monomethyl auristatin F (GSK2857916)
Number of subjects: 0
Study 26370838 — intervention group
Group type: EXPERIMENTAL
Intervention: Chimeric antigen receptor-expressing T cells targeting BCMA
Number of subjects: 0
Study 26370838 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 26371148 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical excision (lumpectomy) without radiation
Number of subjects: 665
Study 26371152 — intervention group
Group type: EXPERIMENTAL
Intervention: Grazoprevir 100 mg once daily and Elbasvir 50 mg once daily coadministered with weight-based Ribavirin twice daily for 12 weeks
Number of subjects: 79
Study 26371152 — intervention group
Group type: EXPERIMENTAL
Intervention: Grazoprevir and Elbasvir with Ribavirin for 12 weeks
Number of subjects: 79
Study 26371702 — intervention group
Group type: EXPERIMENTAL
Intervention: Active CPAP
Number of subjects: 3
Study 26371702 — intervention group
Group type: COMPARATOR
Intervention: Sham CPAP
Number of subjects: 3
Study 26371816 — intervention group
Group type: EXPERIMENTAL
Intervention: Venoarterial extracorporeal membrane oxygenation (VA-ECMO)
Number of subjects: 0
Study 26372191 — intervention group
Group type: EXPERIMENTAL
Intervention: Total percutaneous endovascular aortic repair (PEVAR) using large-diameter sheaths with thoracic, fenestrated, and branched stent grafts.
Number of subjects: 102
Study 26372452 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIG) administered within 5 days after onset of illness
Number of subjects: 2304
Study 26372452 — intervention group
Group type: COMPARATOR
Intervention: Intravenous immunoglobulin (IVIG) administered after 10 days
Number of subjects: 2304
Study 26372465 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate (FF)/Vilanterol (VI) 100/25 μg
Number of subjects: 0
Study 26372465 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate (FF)/Vilanterol (VI) 200/25 μg
Number of subjects: 0
Study 26372465 — intervention group
Group type: EXPERIMENTAL
Intervention: Umeclidinium (UMEC)/Vilanterol (VI) 62.5/25 μg
Number of subjects: 0
Study 26372465 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate (FF) 100 μg
Number of subjects: 0
Study 26372465 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate (FF) 200 μg
Number of subjects: 0
Study 26372465 — intervention group
Group type: EXPERIMENTAL
Intervention: Umeclidinium (UMEC) 62.5 μg
Number of subjects: 0
Study 26373291 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients who would have been excluded from the ISCHEMIA trial (Group A)
Number of subjects: 3102
Study 26373291 — intervention group
Group type: COMPARATOR
Intervention: Patients who did not meet the ISCHEMIA trial exclusion criteria (Group B)
Number of subjects: 3102
Study 26373629 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin 100 mg
Number of subjects: 2313
Study 26373629 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin 300 mg
Number of subjects: 2313
Study 26373629 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2313
Study 26374548 — intervention group
Group type: EXPERIMENTAL
Intervention: Mass spectrometry analysis of urine samples
Number of subjects: 600
Study 26374548 — intervention group
Group type: COMPARATOR
Intervention: Biopsy
Number of subjects: 600
Study 26374908 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive ventilation (NIV) for younger (18-44 y)
Number of subjects: 1225
Study 26374908 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive ventilation (NIV) for middle-aged (45-64 y)
Number of subjects: 1225
Study 26374908 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive ventilation (NIV) for elderly (65-79 y)
Number of subjects: 1225
Study 26374908 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive ventilation (NIV) for aged (≥ 80 y)
Number of subjects: 1225
Study 26374908 — intervention group
Group type: EXPERIMENTAL
Intervention: NIV use for cardiogenic pulmonary edema
Number of subjects: 1225
Study 26374908 — intervention group
Group type: EXPERIMENTAL
Intervention: NIV use with do-not-intubate order
Number of subjects: 1225
Study 26374908 — intervention group
Group type: EXPERIMENTAL
Intervention: NIV with do-not-intubate order for different age groups
Number of subjects: 1225
Study 26375411 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-Delivered Brief Intervention (CBI)
Number of subjects: 12
Study 26375411 — intervention group
Group type: COMPARATOR
Intervention: Counselor-Delivered Individual Brief Intervention (IBI)
Number of subjects: 12
Study 26375437 — intervention group
Group type: EXPERIMENTAL
Intervention: Underwater EMR (UEMR) without submucosal injection
Number of subjects: 27
Study 26375439 — intervention group
Group type: EXPERIMENTAL
Intervention: MET tyrosine kinase inhibitors and a monoclonal antibody targeting MET
Number of subjects: 230
Study 26375439 — intervention group
Group type: COMPARATOR
Intervention: METex14del cases
Number of subjects: 230
Study 26375589 — intervention group
Group type: EXPERIMENTAL
Intervention: Store-and-forward teledermatology referrals
Number of subjects: 391
Study 26375589 — intervention group
Group type: COMPARATOR
Intervention: Conventional referrals
Number of subjects: 391
Study 26375670 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapa (1 mg) and HCQ (200 mg) twice daily for two weeks
Number of subjects: 10
Study 26375808 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate immediate-release (MPH-IR) treatment
Number of subjects: 171
Study 26375808 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 171
Study 26375845 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin (AUC of 5 intravenously every 21 days), Everolimus (5 mg orally once daily), Prednisone (5 mg orally twice daily)
Number of subjects: 26
Study 26375845 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin (AUC of 4 for subsequent patients after dose adjustment)
Number of subjects: 26
Study 26375845 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive nuclear phosphorylated AKT (pAKT) staining
Number of subjects: 26
Study 26375845 — intervention group
Group type: EXPERIMENTAL
Intervention: mTOR inhibitor everolimus added to carboplatin
Number of subjects: 26
Study 26376038 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial fibrillation (AF) in PE patients without DVT
Number of subjects: 295
Study 26376038 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery disease in PE patients without DVT
Number of subjects: 295
Study 26376038 — intervention group
Group type: EXPERIMENTAL
Intervention: Permanent AF in individuals without DVT
Number of subjects: 295
Study 26376038 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxysmal AF in individuals with DVT
Number of subjects: 295
Study 26376038 — intervention group
Group type: COMPARATOR
Intervention: Survival of PE patients with and without DVT
Number of subjects: 295
Study 26376038 — intervention group
Group type: COMPARATOR
Intervention: Cost-relevant clinical outcome of PE patients with and without DVT
Number of subjects: 295
Study 26376038 — intervention group
Group type: EXPERIMENTAL
Intervention: AF in PE patients
Number of subjects: 295
Study 26376038 — intervention group
Group type: EXPERIMENTAL
Intervention: Survival of AF in PE patients
Number of subjects: 295
Study 26376348 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight gain
Number of subjects: 27
Study 26376436 — intervention group
Group type: EXPERIMENTAL
Intervention: cART supplemented with probiotics
Number of subjects: 20
Study 26376436 — intervention group
Group type: COMPARATOR
Intervention: cART
Number of subjects: 20
Study 26376459 — intervention group
Group type: EXPERIMENTAL
Intervention: IV-Erwinia (25,000 IU/m²/dose administered on Monday/Wednesday/Friday for 2 consecutive weeks)
Number of subjects: 30
Study 26376459 — intervention group
Group type: EXPERIMENTAL
Intervention: IV-Erwinia
Number of subjects: 30
Study 26376647 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma protein classifier
Number of subjects: 475
Study 26376647 — intervention group
Group type: COMPARATOR
Intervention: Clinical practices
Number of subjects: 475
Study 26376939 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus 10 mg/day until progression/discontinuation or commercial availability
Number of subjects: 906
Study 26376939 — intervention group
Group type: COMPARATOR
Intervention: Overall population (not specified intervention)
Number of subjects: 906
Study 26377024 — intervention group
Group type: EXPERIMENTAL
Intervention: SAGIT instrument
Number of subjects: 13
Study 26377379 — intervention group
Group type: EXPERIMENTAL
Intervention: SCA1
Number of subjects: 462
Study 26377379 — intervention group
Group type: EXPERIMENTAL
Intervention: SCA2
Number of subjects: 462
Study 26377379 — intervention group
Group type: EXPERIMENTAL
Intervention: SCA3
Number of subjects: 462
Study 26377379 — intervention group
Group type: EXPERIMENTAL
Intervention: SCA6
Number of subjects: 462
Study 26377379 — intervention group
Group type: EXPERIMENTAL
Intervention: SCA1, SCA2, SCA3
Number of subjects: 462
Study 26377415 — intervention group
Group type: COMPARATOR
Intervention: Clear lens
Number of subjects: 30
Study 26377415 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mm optical zone lens
Number of subjects: 30
Study 26377415 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mm optical zone lens
Number of subjects: 30